F. Gary Toback
Corporate Officer/Principal en The University of Chicago .
Cargos activos de F. Gary Toback
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| The University of Chicago | Corporate Officer/Principal | 01/01/1985 | - |
Historial de carrera de F. Gary Toback
Antiguos cargos conocidos de F. Gary Toback.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
NephRx Corp.
 NephRx Corp. BiotechnologyHealth Technology NephRx Corp. provides therapeutic products for the treatment of kidney failures. The firm's flagship product includes NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical development for treatment of delayed graft function in transplant patients. The company was founded in 2001 by Pratik Shah and is headquartered in Kalamazoo, Michigan. | Director Técnico/Científico/I+D | - | - |
Formación de F. Gary Toback.
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
| New York University | Doctorate Degree |
| Boston University | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Israel | 2 |
Operativa
| Doctorate Degree | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorial
| Consumer Services | 5 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
NephRx Corp.
NephRx Corp. BiotechnologyHealth Technology NephRx Corp. provides therapeutic products for the treatment of kidney failures. The firm's flagship product includes NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical development for treatment of delayed graft function in transplant patients. The company was founded in 2001 by Pratik Shah and is headquartered in Kalamazoo, Michigan. | Health Technology |
- Bolsa de valores
- Insiders
- F. Gary Toback
- Experiencia
